[ad_1]
The anti-Covid-19 vaccine from the American company Moderna is 95% effective, according to preliminary data, reports the BBC.
The good results come in the context in which the Pfizer vaccine also lost 92% efficiency, raising hope that these vaccines could lead to an end to the coronavirus pandemic.
Both companies have used innovative approaches to vaccine development. Moderna has announced that it plans to apply for approval of the vaccine in the coming weeks.
However, the data is still preliminary and many key questions remain unanswered.
The vaccine trials involved 30,000 people in the United States, half received two doses of the vaccine four weeks apart. The rest received a placebo infection. The analysis was based on the first 95 cases that became symptomatic with Covid-19; of these, only five had received the vaccine, while the others had been injected with a placebo. The information also shows that there were 11 severe cases of illness with Covid-19, but none of them were in people immunized with the vaccine.
“The efficacy of this vaccine is remarkable. It’s a great day,” said Tal Zaks, Moderna’s chief medical officer.
Moderna’s vaccine may be easier to distribute than Pfizer’s
The Moderna vaccine could pose less of a problem in terms of distribution because, although it uses the same principle, injecting the genetic code of the virus to elicit an immune response, it can be stored and remain stable at a temperature of -20 degrees for a period of time. six months, which would mean it can be stored in normal freezers.
In comparison, Pfizer’s vaccine must be kept at a temperature of -75 degrees Celsius, which poses problems in its storage and distribution, especially in countries that do not have sufficiently capable medical systems.
The European Commission has already signed a contract with the pharmaceutical companies Pfizer and BioNTech for the purchase of 300 million doses of vaccine.
Publisher: Adrian Dumitru
